Veryan closes £5.0m funding round to develop novel BioMimics 3D stent technology and complete the MIMICS pivotal study.

London, 6th October 2011. Veryan Holdings Limited ("Veryan") announced today that it has secured additional funding totaling £5 million (US $8 million) from a syndicate of its existing investors including Imperial Innovations and Seroba Kernel, a European life science venture capital firm. The funds will be employed to finance further development activities and a continuing clinical trial designed to show the clinical benefit of Veryan's unique BioMimics 3D™ stent technology.

Veryan technology

Peripheral vascular disease treatment is one of the fastest growing segments of the cardiovascular device market; the potential market value is in excess of $1 billion. Existing stent technologies have demonstrated significant performance shortfalls including restenosis (re-narrowing) and inadequate mechanical performance leading to suboptimal clinical results.

Veryan is developing a novel stent platform technology that imposes a 3-dimensional helical geometry onto the stented vessel segment which generates physiological swirling blood flow and has been shown to significantly reduce restenosis (re-narrowing) in pre-clinical experiments. In addition, Veryan has established that the 3D geometry confers significant mechanical benefits. The BioMimics 3D stents are more flexible, kink resistant and fracture resistant than traditional stents. The Veryan concept was originally conceived by Professor Colin Caro at Imperial College, London.

Initially targeted at peripheral vessels, the BioMimics 3D technology is also being developed for all vascular stent applications, this will allow the company to target entry into the total stent market (currently estimated in excess of $4 billion).

First in human study

Veryan is currently recruiting a First in Human and CE Mark study at Herz Zentrum, Bad Krozingen, Germany. The Principal Investigator is Professor Thomas Zeller, a recognized global expert in vascular medicine. As well as providing supporting data for achievement of CE Mark status, this study will evaluate the clinical performance attributes of the BioMimics 3D technology against a contemporary control stent and will include the assessment of a number of differentiating features of the Veryan stent technology.

Chas Taylor, Veryan's Chief Executive, commented: *"The results of our first in human study continue to be excellent. We believe that this technology will provide significant clinical benefit in the treatment of vascular disease. We appreciate our investors' continued support for this exciting novel technology"*

For more information contact

Chas Taylor, CEO Veryan Holdings Ltd.
5 City Business Centre, Horsham
West Sussex RH13 5BB

T: +44 (0)1403 258984
E: Chas.taylor@veryanmed.com
W: www.veryanmed.com

Notes to Editors:

About Vascular Disease

The total market for vascular stents to treat occlusive vascular disease exceeds $4 billion p.a. It is a highly profitable and competitive environment with six large corporations and many smaller entrants competing for market share. The market is divided into two key segments, coronary stents (>$3 billion) and peripheral stents (>$1 billion). Despite two decades of stent innovation, two key failure modes remain as critical clinical problems. The first, restenosis (re-narrowing) is a physiological failure mode that arises partly as a result of a proliferation of tissue in response to arterial injury during stent implantation, this process affects the performance of all implanted stents. The second is a physical problem in arteries which have to accommodate considerable compressive and bending forces that cause mechanical deformation of implanted stents. Existing stent designs do not perform well in these environments and the performance of existing stent technology is limited.